Recognition and treatment of Alzheimer's disease: a case-based review
- PMID: 16634468
- PMCID: PMC10833257
- DOI: 10.1177/153331750602100212
Recognition and treatment of Alzheimer's disease: a case-based review
Abstract
Early recognition and treatment initiation are pivotal in managing Alzheimer's disease (AD). Once a diagnosis of AD is made, a treatment plan is developed and should include treatment initiation with cholinesterase inhibitors (ChEIs) to improve cognition, management of comorbid conditions, and treat behavioral symptoms. Caregiver compliance is integral to AD treatment success. The purpose of this report is to present two real case studies of "suspected" AD or related dementia and stress the significance of early and accurate diagnosis in disease management. In case 1, a caregiver reports gradual but progressive loss of memory, and the patient himself complains of memory impairment. Neuroimaging analysis confirms "typical " AD. In case 2, initiation of ChEI therapy is followed by substantial clinical improvement in the face of a complex medical picture, and neuroimaging revealing more neurodegenerative changes than could be accounted for by "pure" AD.
Similar articles
-
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.J Manag Care Pharm. 2008 Jun;14(5):451-61. doi: 10.18553/jmcp.2008.14.5.451. J Manag Care Pharm. 2008. PMID: 18597574 Free PMC article.
-
Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.Curr Med Res Opin. 2006 Jan;22(1):49-59. doi: 10.1185/030079906x80279. Curr Med Res Opin. 2006. PMID: 16393430
-
[Dementia with Lewy Bodies and its differentiation from Alzheimer's disease].Neuropsychiatr. 2007;21(2):63-74. Neuropsychiatr. 2007. PMID: 17640492 German.
-
Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.Clin Neuropharmacol. 2002 Jul-Aug;25(4):207-15. doi: 10.1097/00002826-200207000-00004. Clin Neuropharmacol. 2002. PMID: 12151908 Clinical Trial.
-
Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.CNS Neurosci Ther. 2016 Mar;22(3):159-66. doi: 10.1111/cns.12484. Epub 2016 Jan 18. CNS Neurosci Ther. 2016. PMID: 26778658 Free PMC article. Review.
Cited by
-
Medication compliance in Singaporean patients with Alzheimer's disease.Singapore Med J. 2019 Mar;60(3):154-160. doi: 10.11622/smedj.2018076. Epub 2018 Jun 22. Singapore Med J. 2019. PMID: 29931376 Free PMC article.
-
Effects of polyprenols from pine needles of Pinus massoniana on ameliorating cognitive impairment in a D-galactose-induced mouse model.Age (Dordr). 2014;36(4):9676. doi: 10.1007/s11357-014-9676-6. Epub 2014 Jul 1. Age (Dordr). 2014. PMID: 24981114 Free PMC article.
References
-
- 2. Stommel M, Collins CE, Given BA: The costs of family contributions to the care of persons with dementia. Gerontologist. 1994; 34(2): 199-205. - PubMed
-
- 4. Evans DA: Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990; 68: 267-289. - PubMed
-
- 5. Small GW, McDonnell DD, Brooks RL, et al.: The impact of symptom severity on the cost of Alzheimer's disease. JAm Geriatr Soc. 2002; 50: 321-327. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical